全球 CD47 抑制劑市場：臨床試驗見解與市場機會展望（2028）

Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028

出版日期: 2024年09月01日 | 出版商:

KuicK Research | 英文 240 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

抑制細胞表面蛋白 CD47 已成為一種新型的癌症免疫治療方法，近年來引起了學術界和工業界的興趣。癌細胞通常過度表現CD47，觸發 "別吃我" 訊號通路，幫助惡性細胞逃避免疫監視。 CD47抑制劑目的是透過抑制這種蛋白質來清除癌細胞，使它們更容易受到免疫系統的攻擊，特別是透過增強巨噬細胞的吞噬作用。目前，尚無 CD47 抑制劑已被批准用於治療，但有候選藥物進行 3 期臨床試驗，這可能會在未來幾年內獲得批准。

由於多個候選藥物處於不同的開發階段，CD47 抑制劑的研究和開發領域迅速發展。現在Gilead下的Forty Seven開發的Magrolimab，是最先進的CD47 抑制劑之一。血液惡性腫瘤的早期臨床試驗已顯示出有希望的結果，特別是與其他癌症治療相結合時。此外，實體腫瘤的後期臨床試驗目前評估Magrolimab與docetaxel、Nivolumab、Pembrolizumab、Azacitidine 和 Venetoclax等傳統癌症治療的結合。

ALX Oncology 的Evorpacept（ALX148）是一種抑制 CD47 的高親和力 SIRPa 融合蛋白，也是一個重要的候選者。 Evorpacept 目前多種實體癌和血液癌的多項早期臨床試驗中進行評估，既可以作為單一療法，也可以與廣泛使用的抗癌藥物聯合使用。此外，後期臨床試驗進行中，評估 Evorpacept 合併Trastuzumab、Ramucirumab和Paclitaxel治療 HER2+ 胃癌。其他CD47抑制劑也處於臨床研究的早期階段，包括TQB 2928（正大天晴藥業）、MP 0621（Molecular Partners）、IMC-002（ImmuneOncia Therapeutics）和CC 90002（Celgene）。

中國和美國公司目前佔據市場主導地位，但韓國、澳洲、加拿大和日本也日益進入該市場。透過臨床研究，Shaperon、InnovationBio、Bitterroot Bio 和 ImmuneOncia Therapeutics 等公司 CD47 抑制劑方面取得長足進展。市場競爭激烈，多家企業爭奪市場佔有率。因此，基於安全性、功效和可能的組合策略的差異化對於商業成功非常重要。

本報告檢視了全球 CD47 抑制劑市場，並概述了市場、藥物趨勢、臨床試驗趨勢、區域趨勢以及進入市場的公司的競爭格局。

Global & Regional Market Opportunity Outlook
Insight On More Than 100 CD47 Inhibitor Drugs In Clinical Trials
Global CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
Orphan, Fast Track, Breakthrough Therapy Designation Insight
Key Drugs Initiation & Completion Year
CD47 Clinical Application & Development Outlook By Indication
CD47 Inhibitor Drugs Clinical Developments & Trends By Country
Global CD47 Inhibitor Drug Market Dynamics

Inhibition of the cell surface protein CD47 has emerged as a novel cancer immunotherapy approach that has piqued the interest of both academia and industry in the recent years. Cancer cells often overexpress CD47, which triggers the "don't eat me" signal pathway, thereby helping malignant cells to escape immune surveillance. CD47 inhibitors seek to uncover cancer cells by inhibiting this protein, leaving them open to immune system attack, specifically through increased macrophage phagocytosis. Although no CD47 inhibitor is currently approved for therapeutic usage, the availability of candidates in phase 3 trials suggests that one may be approved in the coming years.

With multiple candidates at varying stages of development, the field of CD47 inhibitor research and development is rapidly evolving. Developed by Forty Seven, which is now a part of Gilead, magrolimab is among the most advanced CD47 inhibitors. In early stage clinical trials for hematological tumors, it has demonstrated encouraging outcomes, especially when combined with other cancer treatments. Furthermore, late stage clinical trials evaluating Magrolimab in solid cancer alongside conventional cancer treatments such as docetaxel, Nivolumab, Pembrolizumab, Azacitidine, and Venetoclax are now under progress.

Another significant candidate is Evorpacept (ALX148) from ALX Oncology, a high affinity SIRPa fusion protein that inhibits CD47. Currently, evorpacept is being assessed as a monotherapy and in combination with widely used anticancer drugs in a number of early phase clinical trials for a variety of solid and hematological tumors. Furthermore, a late-phase trial evaluating Evorpacept in combination with Trastuzumab, Ramucirumab, and Paclitaxel for the treatment of HER2+ gastric cancer is also under progress. A number of other CD47 inhibitors, including as TQB 2928 (Chia Tai Tianqing Pharmaceutical), MP 0621 (Molecular Partners), IMC-002 (ImmuneOncia Therapeutics), and CC 90002 (Celgene), are in the early phases of clinical research.

The emphasis on combination therapies is undoubtedly one of the key trends in clinical development. Combining CD47 inhibitors with other immunotherapies, targeted treatments, and chemotherapy is being studied in an effort to overcome resistance mechanisms and provide synergistic benefits.

Anticipated growth in the global market for CD47 inhibitors is attributed to the rising cancer incidence and increased use of immunotherapies in the upcoming years. The potential of CD47 inhibitors has been acknowledged by a number of prominent pharmaceutical companies, which has resulted in notable partnerships and acquisitions. The commercial interest in this field is demonstrated by Gilead Science's US$ 4.9 billion acquisition of Forty Seven in 2020 and Pfizer's US$ 2.26 billion acquisition of Trillium Therapeutics in 2021.

Although Chinese and American companies presently dominate the market, there is increasing participation from South Korea, Australia, Canada, and Japan. Through clinical research, companies such as Shaperon, InnobationBio, Bitterroot Bio, and ImmuneOncia Therapeutics are making strides with their CD47 inhibitors. The market is becoming increasingly competitive, with several firms striving for market share. Therefore, for commercial success, differentiation based on safety profile, efficacy, and possible combination strategies will be essential.

The market for CD47 inhibitors has both opportunities and challenges. Strong commercial interest and encouraging clinical evidence point to substantial development potential. However, there are challenges to address, such managing toxicity profiles, coming up with the best combination plans, and demonstrating distinct therapeutic advantages over current treatments. As the field develops, biomarker development for response prediction and patient selection will probably become more crucial for clinical development as well as marketing tactics.

In conclusion, the market for CD47 inhibitors globally is an active rapidly expanding area of cancer immunotherapy. In the years to come, CD47 inhibitors could have a big impact on cancer therapy paradigms because there are several candidates in clinical development and a lot of commercial interest.

1. CD 47 As Novel Cancer Immunotherapy Target

2. Global CD47 Inhibitors Drug Clinical Pipeline Overview

2.1 By Country
2.2 By Company
2.3 By Indication
2.4 By Patient Segment
2.5 By Phase
2.6 By Priority Status

3. CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase

3.1 Research
3.2 Preclinical
3.3 Phase I
3.4 Phase I/II
3.5 Phase II
3.6 Phase II/III
3.7 Phase III

4. Global CD47 Inhibitor Drug Market Opportunity Outlook

4.1 Current Market Overview
4.2 Future Outlook & Opportunities

5. CD47 Clinical Application & Development Outlook by Indication

5.1 Solid Cancers
- 5.1.1 Breast Cancer
- 5.1.2 Colorectal Cancer
- 5.1.3 Lung Cancer
- 5.1.4 Urogenital Cancer
- 5.1.5 Gastrointestinal Cancer
5.2 Hematological Malignancies
- 5.2.1 Lymphoma
- 5.2.2 Leukemia
- 5.2.3 Multiple Myeloma
- 5.2.4 Myelodysplastic Syndrome
5.3 Microbial Infections

6. CD47 Inhibitor Drugs Clinical Developments & Trends By Country

6.1 China
6.2 US
6.3 South Korea
6.4 Australia
6.5 Canada

7. Global CD47 Inhibitors Market Dynamics

7.1 Favorable Parameters
7.2 Market Restraints

8. Competitive Landscape

8.1 Adagene
8.2 ALX Oncology
8.3 ImmuneOncia Therapeutics
8.4 ImmuneOnco Biopharma
8.5 Light Chain Bioscience
8.6 Phanes Therapeutics
8.7 Virtuoso Therapeutics

簡介目錄圖表

List of Figures

Figure 2-1: Global - Number of CD47 Inhibitor Drugs Clinical Trial By Country, 2022 Till 2028
Figure 2-2: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Company, 2022 Till 2028
Figure 2-3: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Indication, 2022 Till 2028
Figure 2-4: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Patient Segment, 2022 Till 2028
Figure 2-5: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Phase, 2022 Till 2028
Figure 2-6: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Priority Status, 2022 Till 2028
Figure 5-1: NI-1801 Phase I Study (NCT05403554) - Initiation & Completion Year
Figure 5-2: ALX148 Phase I Study (NCT05868226) - Initiation & Completion Year
Figure 5-3: Ligufalimab Phase II Study (NCT05382442) - Initiation & Completion Year
Figure 5-4: PT217 Phase I/II Study (NCT05652686) - Initiation & Completion Year
Figure 5-5: HMPL-A83 Phase I Study (NCT05429008) - Initiation & Completion Year
Figure 5-6: ALX148 Phase I Study (NCT05524545) - Initiation & Completion Year
Figure 5-7: PT217 Phase I/II Study (NCT05652686) - Initiation & Completion Year
Figure 5-8: AK117 Phase II Study (NCT05382442) - Initiation & Completion Year
Figure 5-9: AK117 Phase I/II Study (NCT05214482) - Initiation & Completion Year
Figure 5-10: AK117 Phase II Study (NCT05960955) - Initiation & Completion Year
Figure 5-11: Evorpacept Phase II/III Study (NCT05002127) - Initiation & Completion Year
Figure 5-12: PT886 Phase I/II Study (NCT05482893) - Initiation & Completion Year
Figure 5-13: CC-96673 Phase I Study (NCT04860466) - Initiation & Completion Year
Figure 5-14: HCB101 Phase I Study (NCT05892718) - Initiation & Completion Year
Figure 5-15: Evorpacept Phase I/II Study (NCT05025800) - Initiation & Completion Year
Figure 5-16: AK117 Phase I/II Study (NCT04980885) - Initiation & Completion Year
Figure 5-17: AK117 Phase I/II Study (NCT06387420) - Initiation & Completion Year
Figure 5-18: TQB 2928 Phase I Study (NCT06008405) - Initiation & Completion Year
Figure 5-19: SL-172154 Phase I Study (NCT05275439) - Initiation & Completion Year
Figure 5-20: SL-172154 Phase Ib Study (NCT05275439) - Initiation & Completion Year
Figure 5-21: Ligufalimab Phase Ib Study (NCT04900350) - Initiation & Completion Year
Figure 6-1: South Korea - Prominent CD47 Inhibitor Developers
Figure 7-1: Global CD47 Inhibitors Market - Drivers & Opportunities
Figure 7-2: Global CD47 Inhibitors Market - Challenges & Restraints